Tubulis Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities

This Tubulis Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.

Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.

Executive BD thesis

Tubulis is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 11 records at the decision date. The lead returned asset is TUB-030, associated with 5T4 x Top I and Advanced Malignant Solid Neoplasm, Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, at Phase 2. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.

A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.

Partnering shortlist

Shortlist interpretation. Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.

Pipeline and evidence-package readout

The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.

Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.

Deal precedents and structure signals

Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.

Financial capacity and partnering pressure

• Praxis Precision Medicines, Inc. - 2023 Annual report: Praxis Precision Medicines, Inc. - 2023 Annual report Revenue The $2.4 million increase in collaboration revenue is associated with the revenue recorded as research services provided and costs incurred under the Collaboration Agreement with UCB that was executed in December 2022. Research and Development Expense The following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands): Year Ended December 31, Change The $68.3 million decrease in research and development expenses was primarily attributable to the following: • $61.4 million decrease in expense related to our Cerebrum™ platform, driven primarily by: ◦ $29.9 million decrease in clinical-related spend for our PRAX-114 program due to our strategic realignment in the second quarter of 2022; ◦ $15.5 million decrease in spend for our PRAX-562 program prima
• CanBas Co.,Ltd. - Annual securities report-21th Period(2019.07.01-2020.06.30): CanBas Co.,Ltd. - Annual securities report-21th Period(2019.07.01-2020.06.30) ②キャッシュ・フロー 営业活动によるキャッシュ・フローは、Stemline社とのライセンス契约に基づくテクニカルアドバイザリー フィーを受领した一方で、日常的な研究费ならびに贩売费及び一般管理费の支出に加えCBP501临床试験费用ならび に次世代CBPプロジェクト関连の支出等により、552,921千円の减少（前事业年度383,671千円の减少）となりまし た。 (投资活动によるキャッシュ・フロー) 投资活动によるキャッシュ・フローには特笔すべき変动はありませんでした（前事业年度変动なし）。 (财务活动によるキャッシュ・フロー) 财务活动によるキャッシュ・フローは、无担保転换社债型新株予约権付社债の発行ならびに新株予约権の発行お よび行使による収入等により、901,659千円の増加（前事业年度683,192千円の増加）となりました。 これらに加え、外货建预金について现金及び现金同等物に系る换算差额△6千円を计上した结果、当事业年度末 の现金及び现金同等物は、前事业年度末と比べ348,659千円増加し、1,112,334千円となりました。 (2) 生产、受注および贩売の実绩 ①生产実绩 当社は研究开発を主体としており、生产実绩を定义することが困难であるため、生产実绩の记载はしていませ ん。 ②受注実绩 当社は受注生产を行っていませんので、受注実绩の记载はしていません。 ③贩売実绩 当事业年度の贩売実绩をセグメントごとに示すと、以下のとおりです。 2. 上记の金额には、消费税等は含まれていません。 CanBas Co.,Ltd. - Annual securities report-21th Period(2019.07.01-2020.06.30) ②キャッシュ・フロー 当事业年度においては、CBS9106にかかる提携契约に基づき、事业収益110,000千円を计上しました。当社の主要 プロダクトであるCBP501について
• CanBas Co.,Ltd. - Annual securities report-16th Period(2014.07.01-2015.06.30): CanBas Co.,Ltd. - Annual securities report-16th Period(2014.07.01-2015.06.30) ６【研究开発活动】 また、CBS9106についても、既存の提携契约において范囲外となっている日本・中国・台湾・韩国を対象とする 提携获得活动を実施しております。 (6）资本の财源および资金の流动性についての分析 当社は、研究开発型ベンチャーであり、将来は当社开発の抗癌剤の上市后に制品贩売による収入を计上する计画 ですが、それまでの先行投资期间においては研究开発费の支出等から営业活动によるキャッシュ・フローはマイナ スを计上する计画です。 先行投资期间における営业活动によるキャッシュ・フローのマイナスについては、现在进めているアライアンス 活动で获得する新规提携パートナーからの契约一时金やマイルストーン、受取研究开発费等の形で営业活动による キャッシュ・フローの确保に努めるほか、必要に応じて适切な时期に资金调达等を実施し、财务活动によるキャッ シュ・フローのプラスにより补填する方针です。 当事业年度の资金状况は、営业活动によるキャッシュ・フローでは、基础研究费を中心とした研究开発费の支出 等により、309,508千円の减少（前事业年度250,382千円の减少）となりました。 投资活动によるキャッシュ・フローは、530千円の减少（前事业年度1,623千円の减少）となりました。 财务活动によるキャッシュ・フローは、新株予约権の行使等による収入により、856,042千円の増加（前事业年 度109,644千円の増加）となりました。 有 CanBas Co.,Ltd. - Annual securities report-16th Period(2014.07.01-2015.06.30) ６【研究开発活动】 これらに加え、外货建预金について现金及び现金同等物に系る换算差额15,996千円を计上した结果、当事业年度 末の现金及び现金同等物は、前事业年度末と比べ562,000千円増加し、885,355千円となりました。 (7）経営

Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.

Current-awareness events and outreach triggers

The Current Awareness news_search call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.

The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.

IP and freedom-to-operate risk screen

The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.

Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.

Recommended deal structures

• Regional license: useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.
• Co-development: appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.
• Option-to-license: reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.
• Research or platform collaboration: suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.
• Structured financing: may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.

Outreach rationale and first-contact plan

1. Identify the decision owner. Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.
2. Lead with one verifiable gap. Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.
3. Attach a concise evidence package. Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.
4. Offer a structure. Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.
5. Define the diligence sequence. Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.

Decision memo

ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH. Tubulis offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.

Required next diligence: refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.

Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.

Data provenance: PatSnap Company & Deal Intelligence MCP (organization_pipeline_fetch, drug_deal_search, financial_report_search) and Current Awareness MCP (news_search); accessed 22 July 2026. Counts, ownership and statuses may change as records update.